🔗 Share this article

As America undertakes sweeping adjustments to its immunization schedules, one figure has emerged in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by expressing skepticism about COVID-19 vaccines during the pandemic and has zeroed in on possible deaths after COVID-19 immunization in her recent tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Program

Health officials had intended to unveil major changes to the childhood vaccine schedule in December, aligning the US with the Danish national calendar, it is understood – a substantial departure that would put the US at odds with many the international standard with insufficient data for improved outcomes. This reveal has been pushed back until the next year.

In place of Vinay Prasad, Høeg is scheduled to address the audience at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

A Shift at the Agency

Høeg's temporary position may indicate a strengthened alliance between the drug and vaccine divisions as Høeg and Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon rolling back already-approved vaccines at the FDA.

The new acting director has often pushed for ending some childhood vaccine recommendations in the US to become more similar to the Danish model, a nation with universal health coverage and a population roughly the size of Wisconsin’s.

So far statements, she has kept her attention on vaccination policy – usually the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has no apparent experience in pharmaceutical research, regulation or leadership, which has been typical for previous directors of the CBER. She has served at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in running a large organization. She lacks background in industry regulation.”

Former directors of CBER would “understand legal statutes and the research of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who ran CBER have had.”

This division has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“Everybody just zeroes in on the new drug program, but the generic drug division approves numerous generic medications. There is also a biosimilars division, over-the-counter program and more, and each of these must be looked after,” Dr. Woodcock said. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a significant management component to the position, which oversees over 5,000 staff members. “It is a massive administrative position, if you execute it properly,” Woodcock added.

Response and Controversial Policies

When asked about concerns about Høeg’s credentials and whether this appointment signifies greater collaboration among regulatory chiefs on immunizations, a press secretary responded that the “concerns are based on flawed premises”.

“This background is consistent with the responsibilities of her role,” the spokesperson explained, pointing to the months Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new priority voucher program, a contentious expedited drug-approval program that apparently worried her predecessors. “By what process are these medications being chosen for this voucher program? Who takes the calls?” Dr. Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards more relaxed oversight of all drugs, with the exception of shots.”

Documented Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if problematic, past, critics said. She published a analysis using unconfirmed crowd-sourced reports to assess the frequency of myocarditis after COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are pose a greater threat than they are.

Part of her “policy goals” for the current federal leadership encompassed changing regulations for novel immunizations and discontinuing “non-essential” vaccines, she stated following the vote on a podcast. At the FDA, Høeg has reportedly proposed excluding adolescent males from receiving Covid vaccines.

“She is an thorough dogmatist who begins with her preconceived notions and works backwards to accommodate the data in a very misleading, fraudulent manner,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|